AUMED, a.s. successfully completed a clinical trial, phase I, of the medicinal product TFI

AUMED, a.s. completed a clinical trial, phase I, of the medicinal product TFI (Transfer Factor) lyophilized mucoadhesive tablet for buccal-oral administration on 18.11.2024. The new medicinal product is based on the results of AUMED’s own research activities in the field of transfer factors. The purpose of this study was to confirm that no significant safety issues would arise in a small sample of study subjects. No adverse effects were observed in this study. Other measurements, such as laboratory results, vital signs or physical findings, did not indicate any safety concerns that would require special attention.